About Luis Javier Leandro-Garcia
Born in Madrid (Spain), Javier holds a degree in Biology (2004) and Biochemistry (2008) and a PhD in Biochemistry, Cell Biology and Biomedicine (2012) from the Autonomous University of Madrid (UAM). He did his PhD thesis on the pharmacogenomics of paclitaxel, a widely used chemotherapeutic drug for the treatment of several types of cancer, at the Spanish National Cancer Research Center (CNIO) in Madrid. In 2014 he moved to New York City (USA) to develop his postdoctoral training at Memorial Sloan Kettering Cancer Center (MSKCC). During this period, he focused his research on murine models of thyroid cancer initiation and progression. He returned to CNIO in 2019 to continue his work studying the genetic and epigenetic mechanisms responsible for the most aggressive forms of thyroid cancer in humans. His ultimate goal in thyroid cancer research is to improve the poor survival of patients affected by the most aggressive and lethal forms of the disease.